Human c-myc Oncogene product,c-myc ELISA Kit

Code CSB-E09260h
Size 96T,5×96T,10×96T
See More Details 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name v-myc myelocytomatosis viral oncogene homolog (avian)
Alternative Names AU016757 ELISA Kit; Avian myelocytomatosis viral oncogene homolog ELISA Kit; bHLHe39 ELISA Kit; c Myc ELISA Kit; Cellular myelocytomatosis oncogene ELISA Kit; Class E basic helix-loop-helix protein 39 ELISA Kit; MGC105490 ELISA Kit; MRTL ELISA Kit; Myc ELISA Kit; Myc protein ELISA Kit; Myc proto oncogene protein ELISA Kit; Myc proto-oncogene protein ELISA Kit; myc-related translation/localization regulatory factor ELISA Kit; MYC_HUMAN ELISA Kit; Myc2 ELISA Kit; myca ELISA Kit; MYCC ELISA Kit; Myelocytomatosis oncogene a ELISA Kit; Myelocytomatosis oncogene ELISA Kit; Niard ELISA Kit; Nird ELISA Kit; oncogene c-Myc ELISA Kit; Oncogene Myc ELISA Kit; OTTHUMP00000158589 ELISA Kit; OTTHUMP00000227763 ELISA Kit; Proto-oncogene c-Myc ELISA Kit; Protooncogene homologous to myelocytomatosis virus ELISA Kit; RNCMYC ELISA Kit; Transcription factor p64 ELISA Kit; Transcriptional regulator Myc-A ELISA Kit; V-Myc avian myelocytomatosis viral oncogene homolog ELISA Kit; v-myc myelocytomatosis viral oncogene homolog (avian) ELISA Kit; zc-myc ELISA Kit
Abbreviation MYC
Uniprot No. P01106
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates, cell lysates
Detection Range 0.312 ng/mL-20 ng/mL
Sensitivity 0.078 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Epigenetics and Nuclear Signaling
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human c-myc in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:1Average %93
Range %87-99
1:2Average %95
Range %91-101
1:4Average %92
Range %88-96
1:8Average %90
Range %86-97
The recovery of human c-myc spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9085-96
EDTA plasma (n=4)9287-97
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
202.404 2.453 2.429 2.341
101.587 1.575 1.581 1.493
51.084 1.066 1.075 0.987
2.50.658 0.699 0.679 0.591
1.250.456 0.487 0.472 0.384
0.6250.251 0.245 0.248 0.160
0.3120.161 0.169 0.165 0.077
00.087 0.089 0.088  
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Q&A and Customer Reviews


Do you know if this Human c-myc Oncogene product,c-myc ELISA kit (CSB-E09260h) will be able to detect myc tagged proteins, or only the whole myc protein itself? The myc tag sequence would be EQKLISEEDL.

Thanks for your inquiry.
This kit detects c-myc Oncogene product. It is designed against full length.
Pls refer to:
Myc tagged protein you mentioned ( a kind of tag protein.
Sorry we didn't do epitope mapping before, so we are not clear if the antibody in the kit can recognize “EQKLISEEDL”or not.

Target Data

Function Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis
Gene References into Functions
  1. the findings of this study demonstrate that hsamiR24 suppresses metastasis in nasopharyngeal carcinoma by regulating the cMyc/EMT axis, suggesting that hsamiR24 may be used as a prognostic factor and as a novel target for the prevention of nasopharyngeal carcinoma metastasis. PMID: 30226609
  2. lncRNA THOR is up-regulated in retinoblastoma, and its over-expression significantly enhances the malignant phenotype transformation of retinoblastoma cells by up-regulating c-myc and TGF2BP1 expression. PMID: 30119193
  3. we demonstrate that neither MYC IHC nor MYC FISH alone is a sufficient screening mechanism for identification of the clinically relevant entities of HGBLwR or DEL PMID: 28868942
  4. Because RPL23 is encoded by a target gene of c-Myc, the RPL23/Miz-1/c-Myc regulatory circuit provides a feedback loop that links efficient RPL23 expression with c-Myc's function to suppress Miz-1-induced Cdk inhibitors and thereby leads to apoptotic resistance in higher-risk myelodysplastic syndrome patients. PMID: 28539603
  5. GATAD2B interacts with C-MYC to enhance KRAS driven tumor growth. PMID: 30013058
  6. low expression of c-Myc protein predicts poor outcomes in patients with HCC with hepatectomy. PMID: 29690860
  7. Combined, these findings suggest that c-Myc could transcriptionally regulate TCRP1 in cell lines and clinical samples and identified the c-Myc-TCRP1 axis as a negative biomarker of prognosis in tongue and lung cancers. PMID: 28623290
  8. Kazakh and Han patients with esophageal squamous cell carcinoma with Glut1 c-myc co-expression had poorer prognosis. PMID: 29629851
  9. MYC activation in papillary clear cell renal cell carcinoma leads to a worse prognosis. PMID: 28593993
  10. could not find any relationship between Bcl-2, c-Myc and EBER-ISH positivity and the low/high IPS groups in classical Hodgkin lymphoma PMID: 29708579
  11. Fluorescence in situ hybridization studies (histologic sections) confirmed translocations of MYC (8q24), BCL2 (18q21) and BCL6 (3q27) in all patients. PMID: 30043475
  12. topical mevastatin accelerates wound closure by promoting epithelialization via multiple mechanisms: modulation of GR ligands and induction of the long noncoding RNA Gas5, leading to c-Myc inhibition. PMID: 29158265
  13. CCND1 , C-MYC , and FGFR1 amplifications were observed in 34.28%, 28.57%, and 17.14% of the 35 samples (invasive ductal breast carcinoma). PMID: 30119151
  14. Data suggest that MYC induction of REV-ERBalpha is both persistent and recurrent across many inducible MYC model systems. PMID: 28332504
  15. HUWE1 overexpression could functionally suppress prostate carcinoma development both in vitro and in vivo, possibly by inverse regulation of c-Myc. PMID: 29966975
  16. Menin functions as an oncogenic regulatory factor that is critical for MYC-mediated gene transcription. PMID: 28474697
  17. High c-myc expression is associated with colorectal cancer. PMID: 30015962
  18. Melatonin disturbs SUMOylation-mediated crosstalk between c-Myc and nestin via MT1 activation and promotes the sensitivity of paclitaxel in brain cancer stem cells. PMID: 29654697
  19. FBP1 modulates the sensitivity of pancreatic cancer cells to BET inhibitors by decreasing the expression of c-Myc. These findings highlight FBP1 could be used as a therapeutic niche for patient-tailored therapies PMID: 30201002
  20. miR135a directly bound to UCA1 and the 3' untranslated region of cmyc, and UCA1 competed with cmyc for miR135a binding. PMID: 30015867
  21. MYC directly regulates DANCR and plays important role in cancer cell proliferation. PMID: 29180471
  22. In this review, we provide support to the hypothesis that the cooperation of c-Myc with transcriptional cofactors mediates c-Myc-induced cellular functions. We produce evidence that recently identified cofactors are involved in c-Myc control of survival mechanisms of cancer cells PMID: 30261904
  23. 4-chlorobenzoyl berbamine (CBBM) inhibits the JAK2/STAT3 pathway, leading to reduced c-Myc transcription. Collectively, these findings suggest that CBBM could be a promising lead compound for treatment of c-Myc-driven diffuse large B cell lymphoma. PMID: 30099568
  24. Results revealed that C-MYC protein is highly expressed in colon cancer tissues, mainly in the cell nucleus and was identified as a direct target for mir-184. C-MYC appeared to participate in cell cycle regulation and malignant transformation to colon cancer. PMID: 28782841
  25. MACC1 and c-Myc are highly expressed in serum and tumor tissues of EC patients. Both are correlated with TNM stage, primary infiltration, and lymph node or distal metastasis. PMID: 29984790
  26. study provides an interesting example using chemical biological approaches for determining distinct biological consequences from inhibiting vs. activating an E3 ubiquitin ligase and suggests a potential broad therapeutic strategy for targeting c-MYC in cancer treatment by pharmacologically modulating cIAP1 E3 ligase activity. PMID: 30181285
  27. The data demonstrated that 10058F4, a cMyc inhibitor, increased the growth inhibition, G0/G1 phase arrest and apoptosis of the NALM6 and CEM cells as induced by dexamethasone (DXM), a type of GC. PMID: 29749488
  28. c-MYC/BCL2 protein co-expression is associated with non-germinal center B-cell in Diffuse Large B-Cell Lymphoma PMID: 29801406
  29. c-Myc was capable of upregulating HP1gamma by directly binding to the E-box element in the first intron of HP1gamma gene, and the upregulated HP1gamma, in turn, repressed the expression of miR-451a by enhancing H3K9 methylation at the promoter region of miR-451a. PMID: 28967902
  30. A subset of pancreatic acinar cell carcinomas shows c-MYC alterations including gene amplification and chromosome 8 polysomy. PMID: 29721608
  31. Expression and Clinical Significance of LC-3 and P62 in Non-small Cell Lung Cancer PMID: 29945702
  32. The findings of the current study demonstrate presence of the IDH1 R132H mutation in primary human glioblastoma cell lines with upregulated HIF-1alpha expression, downregulating c-MYC activity and resulting in a consequential decrease in miR-20a, which is responsible for cell proliferation and resistance to standard temozolomide treatment. PMID: 29625108
  33. a novel signal circuit of Stat3/Oct-4/c-Myc was identified for regulating stemness-mediated Doxorubicin resistance in triple-negative breast cancer PMID: 29750424
  34. MYC amplification and MYC overexpression occurred almost exclusively in secondary cutaneous angiosarcoma in our series. PMID: 29135507
  35. High c-myc expression is associated with the development of prostate cancer. PMID: 29554906
  36. Circular RNA hsa_circRNA_103809 promotes lung cancer progression via facilitating ZNF121-dependent MYC expression by sequestering miR-4302. PMID: 29698681
  37. Authors conclude that quantitative measurements of intratumor heterogeneity by multiplex FISH, detection of MYC amplification and TP53 mutation could augment prognostication in breast cancer patients. PMID: 29181861
  38. PCYT1A was upregulated by MYC, which resulted in the induction of aberrant choline metabolism and the inhibition of B-lymphoma cell necroptosis. PMID: 28686226
  39. Cryptic t(3;8)(q27;q24) and/or MYC-BCL6 linkage associated with MYC expression by immunohistochemistry is frequent in multiple-hit B-cell lymphomas. PMID: 28665415
  40. CD30+ diffuse large B-cell lymphoma has characteristic clinicopathological features mutually exclusive with MYC gene rearrangement and negatively associated with BCL2 protein expression. PMID: 29666157
  41. High MYC amplification is associated with HER2 positive breast cancers in African American women. PMID: 29523126
  42. These data suggest that MYC acts as a master coordinator that inversely modulates the impact of cell cycle and circadian clock on gene expression via its interaction with MIZ1. PMID: 27339797
  43. In our study, the c-myc oncogene was amplified in 11.1% of BPH samples. Bivariate analysis failed to reveal any significant association between oncogene amplification and the clinicopathologic variables examined. PMID: 29234244
  44. Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF1A and HIF1B binding to a MYC enhancer. PMID: 27774982
  45. Data indicate that miR-34a enhanced the sensitivity to cisplatin by upregulation of c-Myc and Bim pathway. PMID: 29060932
  46. Luciferase reporter assay showed that c-Myc, an oncogene that regulating cell survival, angiogenesis and metastasis, was a direct target of miR-376a. Over-expression of miR-376a decreased the mRNA and protein levels of c-Myc in A549 cells. PMID: 28741879
  47. The present findings show that expression of c-MYC has prognostic value in squamous cell carcinoma of the tongue, and could be useful in choice of therapy. PMID: 28393404
  48. Multivariable analysis indicated that IPI (P = 0.002), chemotherapy regimens (P = 0.017), and MYC gene rearrangements (P = 0.004) were independent adverse prognostic factors for all diffuse large B cell Lymphoma(DLBCL) patients in this study. Results demonstrated that the poor survival of DLBCL patients with HBV infection was closely involved in chemotherapy regimens, IPI, and MYC gene rearrangements PMID: 29209623
  49. MYC extra copy in diffuse large B-cell lymphoma is an independent poor prognostic factor PMID: 28776574
  50. The c-Myc/miR-200b/PRDX2 loop regulates colorectal cancer (CRC) progression and its disruption enhances tumor metastasis and chemotherapeutic resistance in CRC. PMID: 29258530
  51. We found that the combination of alpha-mangostin with TRAIL induced apoptosis of SAS cells through the mitochondrial pathway via activation of caspase-9 and -3/7, following release of cytochrome c. This apoptosis was induced by S/G2/M-phase arrest. Immunopositivity for c-Myc was observed in the cytoplasm of tumor cells in 16 (40%) of the 40 cases of human oral squamous cell carcinoma (HOSCC). PMID: 29039600
  52. current data demonstrate that both INSR and IGF1R are directly targeted by C-myc and exert similar effects to promote the tumorigenesis and metastasis of TSCC through the NF-kappaB pathway. PMID: 29518496
  53. clusters of enhancers, such as BENC in the MYC gene, form highly combinatorial systems that allow precise control of gene expression across normal cellular hierarchies and which also can be hijacked in malignancies PMID: 29342133
  54. This study elucidates the molecular basis of the c-Myc/EGLN1-mediated induction of LSH expression that inhibits ferroptosis PMID: 28900510
  55. the findings outlined in the current study suggest that PCAT-1 regulates the invasiveness and drug resistance in CRC cells and that PCAT-1 may promote CRC cell invasion by modulating the expression of c-Myc. PMID: 28884413
  56. data show that Hdac1 and Hdac2 impact on Emu-myc B cell proliferation and apoptosis and suggest that a critical level of Hdac activity may be required for Emu-myc tumorigenesis and proper B cell development PMID: 27886239
  57. we highlight the emerging recognition of MYC and BCL2 coexpression as the most robust predictor of diffuse large B cell lymphoma outcome, and discuss rationally conceived experimental approaches to treat these high-risk patients. PMID: 29198442
  58. knockdown of AP4 abrogated senescence-like phenotype in cells expressing low level of c-Myc, and accelerated cell death in cells with medium level of c-Myc, indicating that AP4 was required for cellular senescence induced by low level of c-Myc. PMID: 29188535
  59. Results provide evidence that myc expression level is regulated by BRD4 in gastric neoplasm through transcriptional and epigenetic regulation. PMID: 28681984
  60. These results indicated that cMyc and Fas regulated the sensitivity of A549 cells to irradiation by regulating caspase8-mediated Bid activation and the subsequent association with the mitochondrial pathway of apoptosis. PMID: 28849062
  61. These results indicate that Merlin/YAP/cMyc/mTOR signaling axis promotes human cholangiocarcinoma (CCA) cell proliferation by overriding contact inhibition. We propose that overriding cMycmediated contact inhibition is implicated in the development of CCA. PMID: 28849072
  62. PLGF promotes Epithelial-mesenchymal transition (EMT) and tumorsphere formation through inducing miR-19a expression by upregulating c-MYC. PMID: 29575299
  63. MYC negatively regulated the expression of genes involved in mitochondrial biogenesis and maintenance but positively regulated genes involved in DNA and histone methylation. Knockdown of MYC in colorectal cancer cells reset the altered metabolism and suppressed cell growth. PMID: 28847964
  64. The combination of PD-L1 and HLA class I represents a novel prognostic biomarker for neuroblastoma. Pharmacologic inhibition of MYCN and MYC may be exploited to target PD-L1 and restore an efficient antitumor immunity in high-risk neuroblastoma. PMID: 28270499
  65. This study identifies a novel signaling involving SYK/c-MYC/MALAT1 as a promising therapeutic target for the treatment of Ewing sarcoma. PMID: 28336564
  66. Overexpression of MYC in diffuse large B-cell lymphoma can be driven by the BCR-PI3K signalling pathway PMID: 28639315
  67. The study suggests that nuclear overexpression of cMYC correlates with tumorigenesis / dedifferentiation in follicular cell derived thyroid carcinomas. PMID: 28974238
  68. data suggest the existence in T-ALL of a disrupted RNA decapping pathway, mediated by the DNA methylation-associated loss of NUDT16, which contributes to the natural history of the disease by stabilizing transforming factors, such as is the case of the leukemogenic protein C-MYC PMID: 28344317
  69. this is the first study to show that PD-L1 gene amplification is not detected, but PD-L1 protein is commonly expressed in ALK- ALCL tumors. More importantly, PD-L1 expression is transcriptionally regulated by STAT3 and MYC in ALK- ALCL, thus providing a biologic rationale for the design of optimal combinations of targeted therapies and immune checkpoint blockade in ALCL and possibly other T-cell lymphomas PMID: 28344319
  70. Data suggest that the co-existence of KRAS mutations and high MYC expression predicts anti-mitotic drug sensitivity. PMID: 27412232
  71. metabolic switching is lineage-specific and not a required step for exit of pluripotency in human pluripotent stem cells and identifies MYC and MYCN as developmental regulators that couple metabolism to pluripotency and cell fate determination. PMID: 28965765
  72. Double-hit lymphoma (DHL) is an aggressive form of DLBCL with an unmet treatment need, in which MYC rearrangement is present with either BCL2 or BCL6 rearrangement PMID: 28952038
  73. Our work demonstrates that MYC expression levels differ between subcutaneous panniculitis-like T-cell lymphoma and erythematosus panniculitis and suggests that this important oncoprotein may play a role in the pathogenesis of subcutaneous panniculitis-like T-cell lymphoma PMID: 28800143
  74. The purpose of this study was to explore gene copy number (GCN) variation of EGFR, HER2, c-MYC, and MET in patients with primary colorectal cancer. PMID: 28764718
  75. MYC and MCL1 cooperate in the maintenance of chemotherapy-resistant cancer stem cells in triple-negative breast cancer. PMID: 28978427
  76. BMH-21 and its analogue 2 bind to G-quadruplex present in the c-MYC promoter, down-regulating c-Myc expression in human tumor cells. This downregulation reflected an early and persistent modulation of cMyc mRNA. PMID: 29229300
  77. Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas. PMID: 29489901
  78. cMyc promotes rhabdomyosarcoma development by inhibiting apoptosis through repression of p21 transcription. PMID: 28765944
  79. MYC-driven tumor initiation relies on cell reprogramming, which is mediated by the activation of MYC-dependent oncogenic enhancers. PMID: 29523784
  80. prognostic effect of imbalanced MYC and PRC2 PMID: 28984200
  81. mdig directly interacts with c-myc and JAK1 in multiple myeloma (MM) cell lines, which contributes to hyperactivation of the IL-6-JAK-STAT3 signaling important for the pathogenesis of MM. PMID: 27833099
  82. we suggested that P2X7R and NLRP3 inflammasome are over-expressed in HNSCC and that the degree of expressional level may represent prognosis of patients. PMID: 28430666
  83. we show that transcription of the LMP1 gene can be negatively regulated by a host transcription factor, c-Myc. PMID: 29118124
  84. While TP53 mutation and MYC amplification were synergistic in promoting tumor progression, PIK3CA mutation was found to have alleviated the oncogenic effect of either the TP53 mutation or MYC amplification, and was associated with a significant reduction in mitotic activity in TP53 mutated and/or MYC amplified breast cancer PMID: 27283966
  85. Mechanistic investigations demonstrated that SNHG3 functioned as a competing endogenous RNA (ceRNA) to 'sponge' miR-182-5p, thus leading to the release of c-Myc from miR-182-5p and modulating the expression of c-Myc. In conclusion, SNHG3 promoted CRC progression via sponging miR-182-5p and upregulating c-Myc and its target genes PMID: 28731158
  86. Study identifies Eya3 as a regulator of PP2A, a major cellular Ser/Thr phosphatase, and uncovers a mechanism of controlling the stability of a critical oncogene, c-Myc. PMID: 29535359
  87. By establishing c-Myc as a direct target of miR-449a, the authors revealed that miR-449a enhanced radiosensitivity by repressing c-Myc expression in LNCaP prostate cancer cells. PMID: 27250340
  88. Baseline enhancer activity of the conserved region specifically on the MYC promoter and its further positive modulation by the SNP risk-allele was shown in vitro. Our findings implicate MYC deregulation as the underlying cause of the observed association. PMID: 27282637
  89. Here the authors show that sublethal activation of Caspase-3 plays an essential, facilitative role in Myc-induced genomic instability and oncogenic transformation. PMID: 28691902
  90. Our findings indicate that Prdx2 might have an important role in the regulation of trophoblast proliferation and apoptosis during early pregnancy, and that its expression is mediated by c-Myc. Thus, these two proteins may be involved in the pathogenesis of RM and may represent potential therapeutic targets PMID: 28661480
  91. Our results indicate that AURKA plays an important role in the activation of EIF4E and cap-dependent translation. Targeting the AURKA-EIF4E-c-MYC axis using alisertib is a novel therapeutic strategy that can be applicable for everolimus-resistant tumors and/or subgroups of cancers that show overexpression of AURKA and activation of EIF4E and c-MYC PMID: 28073841
  92. MYC and hsamiR4235p have been identified to be critical biomarkers in nasopharyngeal carcinoma. PMID: 28586063
  93. Taken together, this study suggests that the OVOL1-OVOL2 axis is a key modulator of c-Myc expression in the shift from in situ epidermal malignancy (Bowen's disease) to invasive squamous cell carcinoma. PMID: 28339425
  94. This study identified PDIA3P as a novel c-Myc interacting long noncoding RNA. PMID: 29501744
  95. Epstein-Barr virus super-enhancers eRNAs important for enhancer-promoter looping at the MYC locus PMID: 27864512
  96. MYC expression significantly correlated with PD-L1 expression and NSCLC patients with MYC-PD-L1 double-positive samples showed poor clinical outcomes. PMID: 28676221
  97. The lower apoptotic activity of low-grade slightly elevated adenomas can be partly attributed to upregulated beta-catenin pathway activity and downregulated c-Myc expression. PMID: 28533663
  98. Inhibition of mitochondrial translation with the antibiotic Tigecycline was synthetic-lethal with Myc activation, impaired respiratory activity and tumor cell survival in vitro, and significantly extended lifespan in lymphoma-bearing mice. PMID: 27635472
  99. MYC Amplification is associated with good response to chemotherapy in Breast Cancer. PMID: 28089283
  100. The results reveal a new connection between p38MAPK, MYC and NOTCH signaling, demonstrate two mechanisms of NOTCH3 regulation and provide evidence for NOTCH3 involvement in prostate luminal cell differentiation. PMID: 28446540

Show More

Hide All

Involvement in disease Burkitt lymphoma (BL)
Subcellular Location Nucleus, nucleoplasm, Nucleus, nucleolus
Database Links

HGNC: 7553

OMIM: 113970

KEGG: hsa:4609

STRING: 9606.ENSP00000367207

UniGene: Hs.202453

Most popular with customers

  Tel: 301-363-4651
  Distributors Worldwide


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1